(PEK-sih-DAR-tih-nib HY-droh-KLOR-ide)
This page contains brief information about pexidartinib hydrochloride and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Pexidartinib hydrochloride is approved to treat:
- Tenosynovial giant cell tumor. It is used in certain adults who have symptoms associated with a severe form of the disease that is not likely to get better with surgery.
Pexidartinib hydrochloride is only available as part of a special program called Turalio REMS (Risk Evaluation and Mitigation).
Pexidartinib hydrochloride is also being studied in the treatment of some types of cancer and other conditions.
More About Pexidartinib Hydrochloride
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Pexidartinib Hydrochloride – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Pexidartinib Hydrochloride – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
